Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 1997

View Archived Issues

Hyalgan introduced in U.S. for osteoarthritis of the knee

First approval for irbesartan

Shire acquires Richwood

North American clinical trials with LiquiVent to be reinitiated

ArQule and GenQuest cancer collaboration

NDA for Colazide accepted for review by FDA

FDA clears new formulation of Imitrex

FDA requests additional manufacturing data before approval of Rituxan

Small peptides developed at Prolifix induce apoptosis in cancer cells

LU-51198 prevents complement-mediated myocardial injury

What's new in Cardiology? Highlights from the 19th Congress of the European Society of Cardiology

Famotidine for schizophrenia

Migraine prophylaxis with bisoprolol

Soluble TNF receptor may benefit patients with coronary artery disease

Cardiovascular benefits of the Mediterranean diet

Past, present and future of arrhythmia therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...